NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Nap B.V. Forgrowth Sells 33,273 Shares of Stock

NewAmsterdam Pharma (NASDAQ:NAMS) major shareholder Nap B.V. Forgrowth sold 33,273 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $25.08, for a total value of $834,486.84. Following the completion of the transaction, the insider now owns 11,778,760 shares in the company, valued at approximately $295,411,300.80. This represents a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.02, for a total transaction of $213,420.60.

NewAmsterdam Pharma Trading Down 4.0 %

NASDAQ:NAMS opened at $23.68 on Wednesday. NewAmsterdam Pharma has a 52 week low of $8.90 and a 52 week high of $26.35. The firm has a 50-day moving average price of $18.82 and a two-hundred day moving average price of $18.61.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Piper Sandler reissued an “overweight” rating and set a $37.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Royal Bank of Canada reissued an “outperform” rating and issued a $31.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, November 7th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, NewAmsterdam Pharma has an average rating of “Buy” and an average price target of $33.80.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several institutional investors have recently modified their holdings of NAMS. Frazier Life Sciences Management L.P. lifted its holdings in NewAmsterdam Pharma by 5.1% during the third quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company’s stock worth $213,396,000 after acquiring an additional 628,251 shares during the period. Janus Henderson Group PLC raised its stake in shares of NewAmsterdam Pharma by 51.1% during the 3rd quarter. Janus Henderson Group PLC now owns 1,540,729 shares of the company’s stock worth $25,607,000 after purchasing an additional 520,772 shares during the period. Millennium Management LLC boosted its holdings in shares of NewAmsterdam Pharma by 23.0% in the 2nd quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock worth $22,388,000 after buying an additional 217,902 shares during the last quarter. Jennison Associates LLC grew its position in NewAmsterdam Pharma by 8.9% during the third quarter. Jennison Associates LLC now owns 1,020,278 shares of the company’s stock valued at $16,937,000 after buying an additional 83,115 shares during the period. Finally, Deerfield Management Company L.P. Series C increased its holdings in NewAmsterdam Pharma by 30.3% during the second quarter. Deerfield Management Company L.P. Series C now owns 869,250 shares of the company’s stock worth $16,698,000 after buying an additional 202,250 shares during the last quarter. 89.89% of the stock is owned by institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.